BNGONCMHealthcare·Medical Instruments & Supplies#54 in industry

Bionano Genomics, Inc.

Reports in 17d· 2026-05-13

-20.1% · 90d

$1.23

+0.02 (+1.65%)

News

(1)

April 2026

Apr 2, 20263 weeks agoDEF 14AHealthcare

Bionano Genomics, Inc. — DEF 14A Filing

BNGOBionano Genomics, Inc.

# 🧾 What This Document Is This is a **proxy statement**, a formal document that public companies must send to shareholders before a big vote. Think of it as an agenda and information packet for the company's annual meeting. It tells you what's being voted on, gives background info, and asks for yo

Read summaryView on SEC EDGAR

Key Data

Market Cap$13.6M

Open$1.23

Prev Close$1.21

Day Range$1.21 – $1.25

52W Range$1.06 – $5.50

Volume67,021

P/E (TTM)—

EPS$-4.85

Dividend Yield—

Beta1.60

Profit Margin-92.59%

Revenue Growth-2.60%

Price Target$5.00(+306.5%)

Next Earnings2026-05-13(17d)

Analyst Ratings

Strong Buy2 analysts

Buy 2Hold 0Sell 0

About

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Healthcare · Medical Instruments & Supplies

95 employees

bionano.com